I can admit I made a mistake in mixing up Kymriah with the Juno drug.
You on the other refuse to admit your mistake that asserted neither was approved and both were behind NWBO in development.
KITE was clearly father along. One can not answer the JUNO question because neither they nor NWBO has made it to the finish line yet and nobody knows exactly where they were. I will bet on JUNO though, just like Cellgene did.
You tried to switch to GBM specifically, but that was not the conversation. The thread originated with BP buyouts, and that was not specific to GMB.
And as of today, the CAR-Ts are further along than path in most solid tumors. NSCLC, BC, Ovarian and a few others. While NWBO spins "pedal to the metal" w/o advancing a single non brain trial in about 5 years.
Market Data 
Markets 
AI
